NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis $2.90 +0.02 (+0.69%) (As of 03:37 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Amylyx Pharmaceuticals alerts: Email Address About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amylyx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.88▼$2.9750-Day Range$1.80▼$2.9252-Week Range$1.58▼$19.95Volume793,028 shsAverage Volume2.11 million shsMarket Capitalization$197.22 millionP/E RatioN/ADividend YieldN/APrice Target$17.60Consensus RatingHold Company OverviewAmylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More… Why You Should NOT Trade This Market (Ad)You'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this different from every other options research you may have seen? Well, for starters... most of them want you to first BUY their service... which is usually thousands of dollars...Just click here to get the full details on the 5-Day Options Trading Challenge, before this offer go Amylyx Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 82nd PercentileAmylyx Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 214th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAmylyx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.27) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amylyx Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.61% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently decreased by 24.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth.Read more about Amylyx Pharmaceuticals' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.61% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently decreased by 24.37%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.83 News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Amylyx Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $321,200.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMLX Stock News HeadlinesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO Acquires $101,200.00 in StockSeptember 17 at 4:50 AM | insidertrades.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director George M. Milne, Jr. Purchases 100,000 SharesSeptember 6, 2024 | insidertrades.com“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.September 19, 2024 | InvestorPlace (Ad)Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are BuyingSeptember 17 at 10:05 AM | benzinga.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates Purchases 40,000 SharesSeptember 17 at 4:52 AM | americanbankingnews.comKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmSeptember 16 at 11:42 AM | globenewswire.comBrokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $17.60September 15, 2024 | americanbankingnews.comDirector Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX)September 9, 2024 | finance.yahoo.comSee More Headlines AMLX Stock Analysis - Frequently Asked Questions How have AMLX shares performed this year? Amylyx Pharmaceuticals' stock was trading at $14.72 on January 1st, 2024. Since then, AMLX stock has decreased by 80.0% and is now trading at $2.95. View the best growth stocks for 2024 here. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.35. The company earned ($1.02) million during the quarter, compared to analysts' expectations of $18.83 million. Amylyx Pharmaceuticals had a negative trailing twelve-month return on equity of 15.51% and a negative net margin of 17.86%. When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Top institutional investors of Amylyx Pharmaceuticals include AQR Capital Management LLC (4.91%), Almitas Capital LLC (2.80%), Millennium Management LLC (2.26%) and Acadian Asset Management LLC (1.78%). Insiders that own company stock include Morningside Venture Investment, Joshua B Cohen, Justin B Klee, Global Investors Lp Viking, George M Milne Jr, Patrick D Yeramian, Gina Mazzariello and Daphne Quimi. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today9/19/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMLX CUSIPN/A CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$17.60 High Stock Price Target$37.00 Low Stock Price Target$3.00 Potential Upside/Downside+496.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$49.27 million Net Margins-17.86% Pretax Margin-54.35% Return on Equity-15.51% Return on Assets-12.86% Debt Debt-to-Equity RatioN/A Current Ratio4.66 Quick Ratio4.66 Sales & Book Value Annual Sales$298.76 million Price / Sales0.67 Cash Flow$0.69 per share Price / Cash Flow4.29 Book Value$6.42 per share Price / Book0.46Miscellaneous Outstanding Shares68,006,000Free Float60,049,000Market Cap$200.62 million OptionableOptionable Beta-0.62 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:AMLX) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
